In the Lab: Re­gen­eron brings its an­ti­body chops to gene edit­ing's biggest prob­lem, aim­ing to 'change the field'

TAR­RY­TOWN, NY — For over three decades, Re­gen­eron has been syn­ony­mous with one thing in the drug in­dus­try: an­ti­bod­ies. Block­busters like Dupix­ent, Eylea, and Covid-19 an­ti­bod­ies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER